

FIGURE 1




FIGURE 2




FIGURE 3

FIG. 3A




FIG. 3B

<u>E1A Core</u>		<u>E2F</u>	<u>E1A Core</u>	
GTGTACACAG	GAAGTGACAA	TTTTCGCGCG	GTTTATAGGCG	GATGTTGTAG
CACATGTGTC	CTTCACTGTT	AAAAGCGCGC	CAAAATCCGC	CTACAACATC
200	210	220	230	240
<u>A I</u>		<u>A II</u>	<u>E2F</u>	
TAAATTGCGG	CGTAACCGAG	TAAGATTGCG	CCATTTTCGC	GGGAAAACTG
ATTAAACCC	GCATTGGCTC	ATTCTAAACC	GGTAAAAGCG	CCCTTTTGAC
250	260	270	280	290
<u>E1A Core</u>	<u>A III</u>	<u>A IV</u>		
AATAAGAGGA	AGTGAAATCT	GAATAATTTT	GTGTTACTCA	TAGCGCGTAA
TTATTCTCCT	TCACTTTAGA	CTTATTAAAA	CACAAATGAGT	ATCGCGCATT
300	310	320	330	340
<u>A V</u>	<u>A VI</u>	<u>A VII</u>		
TATTTGTCTA	GGGCGCGGG	GACTTTGACC	GTTTACGTGG	AGACTCGAAA
ATAAACAGAT	CCCGGCGCCC	CTGAAACTGG	CAAATGCACC	TCTGAGCGGG
350	360	370	380	390


FIG. 3C

A repeat I	5'-GTAAATTTG-3'
A repeat II	GTAAAGATTTG
A repeat III	GTCAAAATCTG
A repeat IV	ATAATTTTG
A repeat V	GTAATAATTTG
A repeat VI	GGGACTTTTG
A repeat VII	GACCGTTTA


CONSENSUS: 5'-GT-N<sub>11</sub>-TTTG-3'

FIGURE 3D


## Product Design for MiniAdFVIII



Version 1: Genomic Sequence Device



Version 2: AAV/ITR Integration Device



Version 3: Episomal Device

FIGURE 4





FIGURE 5A



**FIGURE 5B**




FIGURE 6




FIGURE 7

FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G




FIG. 7H






FIGURE 8



**FIGURE 9**



**FIGURE 10**





FIGURE 11






[illegible][illegible][illegible][illegible]

FIGURE 13

Ad5 Pac Modification with *tetO* Binding Sites

Design #1



Design #2




FIGURE 14

Positions and Sequences of Synthetic Oligos for Ad Pac-GAL4 Modification  
(Design #1 & #2)






FIGURE 15

Positions and Sequences of Synthetic Oligos for Ad Pac- *tetO* Modification (Design #1 & #2)




**FIGURE 16**




**FIGURE 17**

**1 2 3 4**




**- 3.0 kb**

**FIGURE 18**



**FIGURE 19**



**FIGURE 20**

**Albumin 12.5 kb Promoter Fragments**




FIGURE 21






FIGURE 22



**FIGURE 23**



1 Kb DNA Marker

GT2053

GT2061

GT2059

GT2053 BamHI

GT2061 BamHI

GT2059 BamHI

GT2053 XbaI

GT2061 XbaI

GT2059 XbaI

GT2053 ClaI

GT2061 ClaI

GT2059 ClaI


GT2053 XhoI + Sall

GT2061 XhoI + Sall

GT2059 XhoI + Sall

1Kb DNA marker

**FIGURE 24**



Alb-E5

AFP-3

EBB14

FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28

FIG. 28A




FIG. 28B




FIGURE 29





FIGURE 30







**FIGURE 33**  
**MiniAdFVIII-Mediated Expression of hFVIII in Mice**





Fig. 8

FIGURE 34



**FIGURE 35**




FIGURE 36A




FIGURE 36B




FIGURE 36C





FIGURE 36D



**FIGURE 37**




FIGURE 38




FIGURE 39





FIGURE 40




FIGURE 41




FIGURE 42




FIGURE 43




FIGURE 44




FIGURE 45

4 3.16 B7

5.2 kb →

3.0 kb →



FIGURE 46





FIGURE 47




**FIGURE 48**

**ES 19 22 23 33**

**7.8 kb -**



FIGURE 49



**FIGURE 50**




FIGURE 51





FIGURE 52



**FIGURE 53**




FIGURE 54

